Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€406.65

€406.65

1.620%
6.5
1.620%
€489.95
 
19:08 / Tradegate WKN: 882807 / Symbol: VRTX / Name: Vertex / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Vertex Pharmaceuticals Inc. Stock

Vertex Pharmaceuticals Inc. gained 1.620% today.
The stock is an absolute favorite of our community with 45 Buy predictions and no Sell predictions.
With a target price of 489 € there is a positive potential of 20.25% for Vertex Pharmaceuticals Inc. compared to the current price of 406.65 €.
Our community identified positive and negative aspects for Vertex Pharmaceuticals Inc. stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Vertex Pharmaceuticals Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.

Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years

Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Vertex Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Vertex Pharmaceuticals Inc. 1.620% 0.038% 4.505% -12.123% 3.118% 45.774% 59.074%
Exact Sciences -1.900% -7.182% -7.918% -4.193% -22.049% -4.667% -50.456%
Regeneron Pharmaceuticals Inc. 2.180% 0.995% 7.817% -51.415% -29.450% -16.850% -13.268%
Incyte Corp. 2.010% -0.408% -0.711% -2.104% -10.803% -26.004% -35.625%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

When evaluating the financial position of Vertex Pharmaceuticals Inc. (symbol: VRTX), it is evident that the company exhibits robust financial health, especially for a player in the Biotechnology & Medical Research sector. As observed from the provided financial statements, Vertex demonstrates strong revenue growth, impressive profitability, and significant cash reserves. This overall positive trend is accompanied by notable investment in research and development, which is critical for sustaining innovation in the biotech field. However, like any investment, a deeper dive into the various financial metrics is essential to identify both advantages and drawbacks.

Strong Revenue Generation: Vertex reported a total revenue of approximately $9.87 billion for 2023, showcasing healthy growth compared to previous years. The quarterly revenue growth rate of 13.3% indicates consistent demand for its products, which is promising for future sales and market expansion.

Impressive Profit Margins: The profit margin stands at around 39.5%, highlighting Vertex's ability to convert sales into profits effectively. Coupled with an operating margin of 45.2%, it reflects efficient management of operational expenses relative to revenue.

Comments

Prediction Buy
Perf. (%) 0.43%
Target price 442.345
Change
Ends at 14.07.26

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JPMorgan Chase & Co. from $515.00 to $517.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 5.02%
Target price 478.335
Change
Ends at 23.06.26

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $550.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Show more

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for VRTX provided by MarketBeat
Show more

News

The Best Stocks to Invest $1,000 in Right Now: https://g.foolcdn.com/editorial/images/824452/person-smiling-and-looking-at-laptop.jpg
The Best Stocks to Invest $1,000 in Right Now

What if you only had $1,000 to invest in stocks and had to put the money to work today? Which stocks would you buy? That's admittedly not an easy question to answer. I can think of lots of stocks

3 Growth Stocks You Can Buy Right Now Without Any Hesitation: https://g.foolcdn.com/editorial/images/821591/woman-smiling-laptop.jpg
3 Growth Stocks You Can Buy Right Now Without Any Hesitation

You're unlikely to have a warm-and-fuzzy feeling after buying some stocks. Instead, some stocks can keep you awake at night because of their high volatility and risk. The good news, though, is that

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow: https://g.foolcdn.com/editorial/images/819629/gettyimages-1129386267.jpg
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

The three major indexes slid in March and April as investors worried about the impact of President Donald Trump's import tariffs on the economy -- but in recent weeks, optimism about lower, more